Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation

被引:80
作者
Domingo, E
Espín, E
Armengol, M
Oliveira, C
Pinto, M
Duval, A
Brennetot, C
Seruca, R
Hamelin, R
Yamamoto, H
Schwartz, S [1 ]
机构
[1] CIBBIM, Mol Pathol Program, Barcelona, Spain
[2] IPATIMUP, Oporto, Portugal
[3] INSERM, U434, CEPH, F-75654 Paris 13, France
[4] Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido, Japan
关键词
D O I
10.1002/gcc.10310
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BRAF, a serine/threonine kinase of the RAF family, is a downstream transducer of the RAS-regulated MAPK pathway and signals upstream of MEK1/2 kinases. Recently, activating mutations within BRAF have been reported in a high percentage of melanomas and colorectal carcinomas and shown to have oncogenic capabilities. Further, their association to mismatch-repair-deficient tumors has suggested the involvement of the RAS/RAF pathway in the tumorigenesis of microsatellite-unstable colon cancers, and that RAS and RAF mutations are alternative genetic events. We determined whether colorectal mismatch-repair-deficient tumors with BRAF mutations show a specific genotype when compared with tumors with wild-type BRAF, and they can be associated with a particular clinicopathological feature. Here, we report a striking association of BRAF, but not of APC, KRAS2, AXIN2, and TP53 mutations, with proximal mismatch-repair-deficient colon tumors and MLHI hypermethylation. Our results support the hypothesis that proximal and distal colorectal tumors with mismatch repair deficiency harbor different genetic alterations, and we suggest that the involvement of the RAS/RAF pathway in colorectal tumorigenesis is differentially modulated according to tumor location and MLHI inactivation. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:138 / 142
页数:5
相关论文
共 17 条
[1]  
Boland CR, 1998, CANCER RES, V58, P5248
[2]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[3]  
Esteller M, 2000, CANCER RES, V60, P4366
[4]   A GENETIC MODEL FOR COLORECTAL TUMORIGENESIS [J].
FEARON, ER ;
VOGELSTEIN, B .
CELL, 1990, 61 (05) :759-767
[5]  
Fukushima H, 2001, J EXP CLIN CANC RES, V20, P553
[6]   Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines [J].
Gayet, J ;
Zhou, XP ;
Duval, A ;
Rolland, S ;
Hoang, JM ;
Cottu, P ;
Hamelin, R .
ONCOGENE, 2001, 20 (36) :5025-5032
[7]   Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands [J].
Herman, JG ;
Graff, JR ;
Myohanen, S ;
Nelkin, BD ;
Baylin, SB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (18) :9821-9826
[8]  
Hoang JM, 1997, CANCER RES, V57, P300
[9]  
Kane MF, 1997, CANCER RES, V57, P808
[10]   Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating β-catenin/TCF signalling [J].
Liu, WG ;
Dong, XY ;
Mai, M ;
Seelan, RS ;
Taniguchi, K ;
Krishnadath, KK ;
Halling, KC ;
Cunningham, JM ;
Qian, CP ;
Christensen, E ;
Roche, PC ;
Smith, DI ;
Thibodeau, SN .
NATURE GENETICS, 2000, 26 (02) :146-147